+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cluster Of Differentiation 3"

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019 - Product Thumbnail Image

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 84 Pages
  • Global
From
Bispecific Antibody Market By Product (Blinatumomab, Emicizumab, Others), By Applications (Cancer, Hemophilia, Others), By End User (Hospitals, Cancer Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Thumbnail Image

Bispecific Antibody Market By Product (Blinatumomab, Emicizumab, Others), By Applications (Cancer, Hemophilia, Others), By End User (Hospitals, Cancer Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • July 2023
  • 382 Pages
  • Global
From
Loading Indicator

The Cluster of Differentiation 3 (CD3) market is a subset of the oncology drug market that focuses on drugs that target the CD3 molecule. CD3 is a protein found on the surface of T-cells, which are a type of white blood cell that plays a key role in the body's immune system. CD3-targeting drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. These drugs work by blocking the CD3 molecule, which prevents the T-cells from attacking healthy cells and helps to reduce the growth of cancer cells. Some of the companies in the CD3 market include Novartis, Merck, Pfizer, and Bristol-Myers Squibb. These companies have developed a range of CD3-targeting drugs, including Imbruvica, Keytruda, and Opdivo. These drugs have been approved by the FDA for the treatment of various types of cancer and are widely used in the oncology field. Show Less Read more